Johnson & Johnson (JNJ) Profit After Tax Growth (3y) (2012 - 2026)
Johnson & Johnson (JNJ) Profit After Tax Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 0.97% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 39.29% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 12.02% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 19.41% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 19.87% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -129.22% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -37.78% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -54.33% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -34.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 0.97% |
| Mar 29, 2026 | 133.08% |
| Dec 28, 2025 | 13.27% |
| Sep 28, 2025 | 4.94% |
| Jun 29, 2025 | 4.77% |
| Mar 30, 2025 | 28.79% |
| Sep 29, 2024 | -9.77% |
| Jun 30, 2024 | -9.29% |
| Mar 31, 2024 | -19.32% |
| Dec 31, 2023 | 33.47% |
| Oct 1, 2023 | 94.20% |
| Jul 2, 2023 | 14.03% |
| Apr 2, 2023 | -27.75% |
| Jan 1, 2023 | -4.25% |
| Oct 2, 2022 | 36.50% |
| Jul 3, 2022 | -4.96% |
| Apr 3, 2022 | 11.16% |
| Oct 3, 2021 | -2.32% |
| Jul 4, 2021 | 16.66% |
| Apr 4, 2021 | 12.37% |